EndoCyclic Therapeutics is a biopharmaceutical company focused on the discovery and development of best-in-class and first-in-class non-hormonal, precision medicines for women’s health and oncology. Utilizing our innovative precision peptide technology, we are committed to revolutionizing endometriosis care with the development of the first potential disease-modifying therapeutic for endometriosis designed to eliminate lesions and associated symptoms. EndoCyclic is also advancing an investigational imaging diagnostic agent for endometriosis designed to detect all subtypes of the disease, including small superficial lesions, with the goal of providing a non-invasive alternative to surgical diagnosis. Our expanding portfolio further includes therapeutics and diagnostics in oncology (including endometrial and colon cancer) and other women’s health diseases.

Endometriosis affects over 10% of women globally and is the leading cause of infertility and disability among women of reproductive age. Despite its prevalence, it remains one of the most overlooked conditions in women’s health. At EndoCyclic Therapeutics, our team is determined to address this gap by discovering new solutions that have the potential to definitively diagnose and treat these conditions.

Our precision peptides are specifically engineered for exclusive uptake and activity at the site of disease. In therapeutic applications, this approach enables targeted delivery with the potential to reduce off-target side effects. In diagnostic applications, it enables visualization of lesions that otherwise remain undetected with conventional imaging.

For more information about how we are driving change in women’s health and oncology, and bringing awareness to these critical issues, please visit our website at www.endocyclictherapeutics.com.

EndoCyclic Therapeutics

Org chart

Teams

Offices